Yanagisawa T, Kimura T, Mori K, Suzuki H, et al. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer. Prostate 2021 Sep 24. doi: 10.1002/pros.24243.
PMID: 34559410